Lupin’s isoniazid/rifapentine tablet prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Recent Highlights
IVD
On 14 October 2024 WHO listed the second mpox IVD under the WHO Emergency Use Listing (EUL) procedure.
For Public Consultation: New proposed version of the Guidance on reportable changes to IVDs
IVD
WHO is seeking for public comments on a new proposed version of the Guidance on reportable changes to IVDs (deadline for submission of comments by 15 November 2024).
Public consultation on proposed revisions to the WHO Prequalification of in vitro diagnostics assessment process
IVD
WHO has identified the need to revise the WHO prequalification processes for IVDs to address the growing need for increased access to quality assured IVDs in low and middle-inco
Active Pharmaceutical Ingredient (API) Prequalified
M
Dolutegravir (sodium) manufactured by Aurore Life Sciences Private Limited has been prequalified by the WHO Prequalification Team medicines under its API prequalification procedure.
Shanghai Desano’s nirmatrelvir + ritonavir tabl prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Sun Pharmaceutical’s atazanavir/ritonavir tabl prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list: